X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The two companies will collaborate to maximize the impact of MoonLake’s nanobody-based therapy, M1095 (sonelokimab) in hidradenitis suppurativa (HS) and active psoriatic arthritis (PsA), two underdiagnosed diseases with significant unmet patient needs.
Lead Product(s): Sonelokimab
Therapeutic Area: Dermatology Product Name: M1095
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Komodo Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 10, 2024
Details:
M1095 (sonelokimab) is an investigational ~40 kDa humanized Nanobody® consisting of three VHH domains covalently linked by flexible glycine-serine spacers. It is being evaluated for the treatment of hidradenitis suppurativa.
Lead Product(s): Sonelokimab
Therapeutic Area: Dermatology Product Name: M1095
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
M1095 (sonelokimab) is a humanized nanobody consisting of three VHH domains covalently linked by flexible glycine-serine spacers. It selectively binds with IL-17A and IL-17F and inhibit IL-17A/A, IL-17A/F, and IL-17F/F dimer, which investigated for moderate-to-severe hidradenitis suppurativa.
Lead Product(s): Sonelokimab
Therapeutic Area: Dermatology Product Name: M1095
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2023
Details:
M1095 (sonelokimab) is a humanized nanobody consisting of three VHH domains covalently linked by flexible glycine-serine spacers. It selectively binds with IL-17A and IL-17F and inhibit IL-17A/A, IL-17A/F, and IL-17F/F dimer, which investigated for psoriatic arthritis.
Lead Product(s): Sonelokimab
Therapeutic Area: Immunology Product Name: M1095
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Details:
MoonLake intends to use the net proceeds to fund the ongoing advancement of M1095 (sonelokimab), a trivalent monomeric nanobody that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F for the treatment of inflammatory diseases.
Lead Product(s): Sonelokimab,Adalimumab
Therapeutic Area: Dermatology Product Name: M1095
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 28, 2023
Details:
MoonLake intends to use the proceeds to fund the ongoing advancement of M1095, a novel investigational Nanobody® for the treatment of inflammatory disease. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.
Lead Product(s): Sonelokimab
Therapeutic Area: Immunology Product Name: M1095
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 26, 2023
Details:
M1095 (sonelokimab) is a humanized nanobody consisting of three VHH domains covalently linked by flexible glycine-serine spacers. It selectively binds with IL-17A and IL-17F and inhibit IL-17A/A, IL-17A/F, and IL-17F/F dimer, which investigated for hidradenitis suppurativa.
Lead Product(s): Sonelokimab,Adalimumab
Therapeutic Area: Dermatology Product Name: M1095
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2023
Details:
The collaboration aims to develop an autoinjector for clinical and potential subsequent commercial supply of MoonLake’s Nanobody® M1095 (sonelokimab) by using SHL Medical's market-proven Molly® modular platform technology.
Lead Product(s): Sonelokimab,Adalimumab
Therapeutic Area: Immunology Product Name: M1095
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: SHL Medical AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 03, 2023
Details:
M1095 (sonelokimab) is a humanized nanobody® consisting of three VHH domains covalently linked by flexible glycine-serine spacers. It selectively binds with high affinity to IL-17A and IL-17F and inhibits IL-17A/A, IL-17A/F, and IL-17F/F dimers.
Lead Product(s): Sonelokimab
Therapeutic Area: Dermatology Product Name: M1095
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
MoonLake plans to execute on its development program to unlock the potential of M1095 (Sonelokimab), the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients with inflammatory diseases.
Lead Product(s): Sonelokimab
Therapeutic Area: Immunology Product Name: M1095
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
